Endometriosis

Andrographis paniculata has strong evidence from systematic reviews for relieving symptoms of acute respiratory tract infections including bronchitis. Its active compound andrographolide acts via immunomodulation and antiviral/antibacterial effects. A 2023 systematic review confirmed its mechanistic and clinical plausibility for uncomplicated acute respiratory infections.

Andrographolide is the principal active diterpene lactone of Andrographis paniculata and the mechanistic basis for the herb's clinical efficacy in acute respiratory infections including bronchitis. It exerts immunomodulatory and antiviral effects confirmed by a 2023 systematic review. NF-κB inhibition is the key anti-inflammatory pathway.

Astragalus (Astragalus membranaceus, Huang Qi) is extensively used in TCM as an immune-modulating herb for chronic respiratory conditions including bronchitis. Systematic reviews of Chinese clinical trials support its use for reducing bronchitis exacerbations and improving respiratory immune function. A double-blind RCT found 3 g daily for 8 weeks significantly reduced exacerbation frequency.

Boswellia (Boswellia serrata, Indian frankincense) has demonstrated anti-inflammatory efficacy in respiratory inflammatory conditions including chronic bronchitis and asthma. A placebo-controlled RCT (40 asthmatic patients, 300 mg three times daily for 6 weeks) showed significant improvement in FEV1, PEF, and attack frequency. Its boswellic acids inhibit 5-lipoxygenase, reducing LTB4, a key mediator of bronchial inflammation.

Boswellic acids are the primary active triterpenoids of Boswellia serrata with demonstrated inhibition of 5-lipoxygenase, reducing leukotriene B4 production in bronchial inflammation. A placebo-controlled clinical trial showed 70% improvement in respiratory function in patients receiving Boswellia extract standardized to boswellic acids vs. 27% in placebo. They are the mechanistic basis for Boswellia's anti-inflammatory use in bronchitis and asthma.

Bromelain, the proteolytic enzyme complex from pineapple, has demonstrated therapeutic benefits for bronchitis and sinusitis through mucolytic, anti-inflammatory, and immunomodulatory mechanisms. German Commission E recognizes bromelain for inflammation of the upper and lower respiratory tract. Evidence reviews document its efficacy for reducing sputum viscosity and bronchial inflammation.

Early clinical research, including the Ziolo & Samochewiec (1998) study, demonstrated that petasites extract improved lung ventilation markers and reduced bronchial reactivity in patients with chronic obstructive bronchitis. RxList and MSKCC note early evidence for this use. The antispasmodic and anti-inflammatory mechanisms are the same as those relevant to asthma.

Carvacrol is the secondary major phenol in thyme oil alongside thymol, contributing to thyme's Commission E-approved use for bronchitis. It has demonstrated antimicrobial, anti-inflammatory, and bronchospasmolytic properties in preclinical studies. It is also the primary active constituent of oregano essential oil traditionally used for respiratory conditions.

Chymotrypsin has documented use as a mucolytic and anti-inflammatory agent in bronchitis, used via inhalation or orally to reduce airway inflammation and loosen phlegm. Authoritative sources including WebMD and RxList reference this clinical use. The mucolytic mechanism is well-characterized: chymotrypsin directly decreases mucus viscosity.

Cineole (1,8-cineole/eucalyptol) is the main constituent of eucalyptus oil with specific clinical evidence for acute bronchitis from a placebo-controlled double-blind RCT (PMC3842692) demonstrating significantly faster dissipation of acute bronchitis symptoms versus placebo. It acts as a mucolytic, bronchodilator, and NF-κB-inhibiting anti-inflammatory agent.

Cordyceps (Cordyceps sinensis/militaris) is used in Traditional Chinese Medicine for chronic bronchitis, cough, and asthma, supported by clinical studies and systematic reviews showing improvement in respiratory function. Multiple clinical trials report reductions in chronic bronchitis exacerbations and improved FEV1, FVC, and exercise capacity with Cordyceps preparations.

Curcumin is included in the 2025 Frontiers in Pharmacology PROSPERO-registered systematic review on chronic bronchitis. A 2026 Nutrients review rated Curcuma longa (curcumin source) as having robust clinical evidence for RTIs. It inhibits NF-κB, reduces bronchial cytokine production, and suppresses mucin gene expression and goblet cell hyperplasia relevant to bronchitis pathology.

Echinacea species are among the best-studied botanicals for immune support in respiratory infections including acute bronchitis. A 2023 systematic review placed Echinacea alongside Andrographis and Pelargonium as herbs with promising clinical effects in acute uncomplicated respiratory tract infections. A 2026 Nutrients review rated Echinacea spp. as having robust clinical evidence for RTIs.

Echinacea purpurea is the most studied Echinacea species for respiratory tract infections including bronchitis. Multiple RCTs and systematic reviews, including Cochrane assessments, found statistically significant reductions in respiratory infection symptom duration and severity. Its polysaccharides and alkylamides drive immunostimulation and anti-inflammatory effects in bronchial tissue.

Elder (Sambucus nigra) berries and flowers are supported by robust clinical evidence for respiratory tract infections including bronchitis per a 2026 Nutrients systematic review. Multiple RCTs demonstrate reduction in respiratory infection duration and severity. EMA recognizes elderflower as a traditional herbal medicine for upper respiratory catarrh.

Elderberry (Sambucus nigra) is supported by robust clinical evidence for respiratory tract infections. A 2026 Nutrients systematic review rated it alongside Echinacea and Pelargonium as having robust evidence for RTIs. A meta-analysis of four RCTs (1,016 participants) found elderberry substantially reduced upper respiratory symptoms by a mean of 3.86 days.

Ephedrine is the primary alkaloid of Ephedra sinica with well-characterized bronchodilatory activity via beta-adrenergic receptor stimulation. It is pharmacologically validated for bronchospasm relief relevant to bronchitis. Its mechanism is analogous to synthetic bronchodilators used in conventional medicine and it has been used clinically as a bronchodilator for decades.

Eucalyptus oil and its primary constituent cineole have clinical evidence for acute bronchitis from a double-blind RCT showing significantly faster symptom resolution. German Commission E and EMA support eucalyptus for respiratory tract catarrh. A 2025 Frontiers systematic review identifies Eucalyptus globulus among 13 medicinal plants with evidence for chronic bronchitis.

European Elder (Sambucus nigra) shares the same botanical species and clinical evidence base as Elderberry for respiratory tract infections including bronchitis. A 2026 Nutrients review rated Sambucus nigra as having robust clinical evidence for RTIs alongside Echinacea and Pelargonium. EMA recognizes elderflower as a traditional herbal medicinal product for upper respiratory catarrh.

Fritillary is explicitly documented in clinical TCM practice for bronchitis, with phytochemical evidence showing suppression of bronchial inflammation. Pharmacological reviews identify FRC and FRT as having notable effects on bronchitis. The herb inhibits mucin gene expression in bronchial epithelial cells and reduces pro-inflammatory cytokines.

Garlic (Allium sativum) inhibited infectious bronchitis virus in a 2016 peer-reviewed study and is listed among proposed treatments for bronchitis in multiple authoritative sources. It has long-standing traditional use across Ayurveda, TCM, and European herbal medicine for respiratory infections. Allicin and organosulfur compounds provide antimicrobial, antiviral, and anti-inflammatory effects.

Garlic bulb (Allium sativum) has direct laboratory evidence inhibiting infectious bronchitis virus (2016, Avicenna Journal of Phytomedicine, PMID 27516987). It is listed in authoritative traditional medicine reviews as a bronchitis remedy. Allicin and diallyl sulfide constituents provide antiviral, antibacterial, and expectorant activity relevant to acute bronchitis.

Pelargonium sidoides (EPs 7630) has strong clinical trial and Cochrane review evidence for acute bronchitis in adults and children. The EMA has approved P. sidoides for respiratory tract infections including bronchitis. This is one of the best-evidenced herbal remedies for this condition.

Ginseng (Panax ginseng, American ginseng) has clinical evidence for reducing respiratory tract infections and improving respiratory immune function. A 2026 Nutrients review included ginseng-related compounds among clinically evaluated plant agents for RTIs. A double-blind RCT (323 adults) found American ginseng extract significantly reduced incidence and duration of respiratory illness. It is used in TCM for chronic bronchitis.

G. littoralis is formally documented in Chinese clinical practice for chronic bronchitis and is listed in the Chinese Pharmacopoeia for lung conditions. The 2024 PMC study (PMC11547663) and ScienceDirect 2023 review both cite chronic bronchitis as a recognized clinical application. Antitussive and anti-inflammatory preclinical evidence supports this use.

Glycyrrhetinic acid is the hydrolysis product of glycyrrhizin from licorice root, acting as the pharmacologically active aglycone mediating most of glycyrrhizin's anti-inflammatory effects in bronchial tissue. It potentiates endogenous cortisol via 11β-HSD2 inhibition and inhibits NF-κB and phospholipase A2, providing corticosteroid-like bronchial anti-inflammatory effects.

Glycyrrhizin is the primary active compound of licorice root with demonstrated antiviral, anti-inflammatory, and expectorant properties relevant to bronchitis. It inhibits NF-κB and reduces mucus hypersecretion. NCCIH documents it as the main bioactive constituent of licorice, which is recognized by Commission E and ESCOP for upper respiratory catarrh.

Honey is supported by a clinical randomized trial for managing acute bronchitis. A 2023 multiarm RCT (Llor et al., Family Practice) compared honey versus antitussives and anticholinergics for uncomplicated acute bronchitis, finding honey to be an effective usual-care alternative. WHO endorses honey as a demulcent for cough and respiratory tract irritation.

Clinical evidence supports the combination of horseradish root and nasturtium (Angocin Anti-Infekt N) for acute bronchitis. A prospective cohort study of 634 bronchitis patients found efficacy comparable to antibiotics with fewer adverse effects. A separate randomised placebo-controlled trial (n=384) confirmed healing benefit. Evidence is for the combination product.

Ivy leaf (Hedera helix) extract is clinically authorized in several European countries as a medicinal product specifically for acute bronchitis. A 2025 three-arm multicenter RCT (325 adults) demonstrated ivy extract was non-inferior to Ivy/Thyme and Thyme/Primrose combinations on the Bronchitis Severity Score at day 7. Its saponin hederacoside C provides secretolytic and spasmolytic effects in bronchial tissue.

As a precursor to cysteine and thus to NAC, L-cystine underpins the mucolytic, antioxidant, and anti-inflammatory mechanisms relevant to bronchitis management. NAC—the clinically validated cysteine prodrug—has documented RCT and regulatory evidence for both acute and chronic bronchitis. Direct L-cystine bronchitis trials are not available, but the mechanistic lineage is biochemically direct.

Luteolin is the subject of a dedicated 2025 Frontiers in Pharmacology review on its regulatory mechanisms in inflammatory respiratory diseases. It inhibits NF-κB and PI3K/Akt pathways in bronchial inflammation models and is cited in the 2025 chronic bronchitis systematic review as a flavonoid with demonstrated effects in inflammatory respiratory conditions.

Malabar nut (Justicia adhatoda, Vasaka) is used in Ayurvedic and Unani medicine specifically for bronchitis, with the Indian Pharmacopoeia listing Vasaka syrup and liquid extract for respiratory use. Primary alkaloids vasicine and vasicinone have demonstrated bronchodilatory and expectorant effects in vitro and in vivo. It is used in commercial respiratory preparations in India, Germany, and Sweden.

NAC has extensive RCT evidence for both acute and chronic bronchitis. A meta-analysis of 11 RCTs (775 patients) found NAC significantly reduced chronic bronchitis exacerbation frequency (RR=0.81). A second meta-analysis of 13 studies (4,155 patients) confirmed fewer exacerbations (RR=0.75, p<0.01). A double-blind RCT found 200 mg NAC thrice daily significantly reduced cough, sputum volume, and viscosity in acute bronchitis.

Naringin is specifically documented in the 2025 Frontiers in Pharmacology PROSPERO-registered systematic review on chronic bronchitis. In guinea pig models of cigarette smoke-induced chronic bronchitis, naringin significantly reduced inflammatory cell counts, cytokines (IL-8, TNF-α), MPO activity, and cough frequency while enhancing antioxidant activity in bronchial tissue.

Pelargonium sidoides root extract (EPs 7630) is one of the best-evidenced herbal treatments specifically for acute bronchitis, with multiple placebo-controlled RCTs and systematic reviews demonstrating significant symptom relief. A 2026 Swiss pragmatic RCT further validated its use versus usual care. It acts through antiviral, indirect antibacterial, immunomodulatory, and expectorant mechanisms.

Both P. major and P. lanceolata have clinical trial evidence in bronchitis. A double-blind RCT with P. major syrup showed significant reduction in cough severity (BSS score) in acute bronchitis. An older trial in chronic bronchitis with P. major preparation showed rapid improvement in 80% of patients. Commission E and ESCOP endorse P. lanceolata for catarrh of the airways.

A double-blind randomized controlled trial tested Plantago major syrup (30 ml/day for 10 days) in 80 patients with acute bronchitis. The P. major group showed significantly lower Bronchitis Severity Scale scores, cough frequency, sputum volume, and chest wall pain compared to placebo. This represents direct clinical evidence for P. major in bronchitis.

Platycodon root is formally indicated for bronchitis in TCM, Kampo, and Korean traditional medicine, with the Chinese Pharmacopoeia and ethnopharmacological records confirming millennia of use. A 2025 ScienceDirect study found platycodon mitigates cigarette smoke-induced chronic bronchitis inflammation via TLR4/MyD88/NF-κB pathway inhibition. Network pharmacology and phytochemical studies have mapped its multi-target mechanisms.

Quercetin is specifically included in the 2025 Frontiers in Pharmacology PROSPERO-registered systematic review on chronic bronchitis. A preclinical study showed quercetin at 0.05–0.1 g/kg for 5 days reduced cough frequency comparably to pentoxyverine citrate in bronchitis models. It also suppresses mucin expression, a hallmark of chronic bronchitis.

Serratiopeptidase has been clinically studied for bronchitis and chronic airway disease, with evidence for reducing sputum viscosity, elasticity, and neutrophil count. A 2003 randomized open-label trial (Nakamura et al., Respirology, n=29) found 30 mg/day for 4 weeks decreased sputum weight, viscosity, and elasticity versus no treatment. It has been used clinically for bronchitis in Japan and Europe for decades.

Thyme (Thymus vulgaris) is approved by the German Commission E specifically for symptoms of bronchitis and whooping cough. A large 361-patient double-blind placebo-controlled study found a thyme-primrose root combination significantly enhanced recovery from acute bronchitis. A 2025 three-arm RCT (325 adults) confirmed thyme/primrose non-inferior to ivy extract on Bronchitis Severity Score.

Thymol is the primary active phenol of thyme oil with documented antimicrobial, expectorant, and bronchospasmolytic effects that underlie thyme's Commission E-approved use for bronchitis. It is the key constituent responsible for thyme's clinical efficacy in bronchitis preparations registered in Germany, confirmed by a 2023 mechanistic systematic review.

Bronchitis is the most robustly evidenced clinical indication for Thymus vulgaris, with multiple prospective double-blind placebo-controlled multicentre RCTs demonstrating significant reductions in cough frequency and bronchitis severity scores. Both German Commission E and ESCOP monographs formally approve thyme for bronchitis. Thymol's secretolytic, spasmolytic, and antimicrobial mechanisms are well characterised.

Ethanolic extract of T. cordifolia is an ingredient in 'Septilin,' a commercial Ayurvedic formulation recommended and used clinically for bronchitis treatment. Its anti-inflammatory and antimicrobial properties support this use.

Vasicine is the primary alkaloid of Adhatoda vasica (Malabar nut) with demonstrated bronchodilatory, expectorant, and anti-tussive activities in vitro and in vivo. It is the pharmacopoeial active constituent in Vasaka syrup (Indian Pharmacopoeia) specifically for bronchitis. It is the structural precursor of bromhexine, a widely used pharmaceutical mucolytic for bronchitis.

Vasicinone is the principal metabolite of vasicine from Adhatoda vasica with demonstrated in vitro bronchodilatory activity. It is documented alongside vasicine as a therapeutic agent for bronchitis in patent literature (US Patent 11351213). It is also a recognized pharmacologically active compound in Ayurvedic Vasaka preparations listed in the Indian Pharmacopoeia.

Traditional Himalayan and Indian medicine uses A. spectabilis leaf juice and essential oil for bronchitis. This is documented in multiple ethnobotanical surveys of Nepal. Preclinical antitussive and bronchodilatory data provide biological plausibility.

Ajwain is widely used in traditional Ayurvedic and Unani medicine for bronchitis, leveraging its bronchodilatory, expectorant, and antimicrobial properties. Steam inhalation with ajwain is a traditional home treatment for bronchitis symptoms. While bronchodilatory effects have clinical evidence, bronchitis-specific clinical trials are absent.

Alkanet is traditionally used internally for bronchitis, bronchial catarrh, and persistent cough. All plant parts are described as demulcent and expectorant in herbal references. Use for bronchial inflammation is documented in European folk medicine and in Indian traditional medicine (ratanjot).

Galangal rhizome is used in Indian indigenous medicine, Ayurveda, and TCM for bronchitis and bronchial catarrh. In Indian medicine it is classified as an expectorant and decongestant. It appears in traditional formulations for respiratory complaints including chronic bronchitis. No dedicated human trials exist.

Anemarrhena has a documented traditional history of use for chronic and acute bronchitis in TCM and East Asian medicine. Its actions of moistening the lungs, clearing heat, and antibacterial properties against Staphylococcus aureus and other pathogens underlie this traditional use.

Use of annatto leaf preparations as expectorants and for treatment of bronchitis, cough, and pulmonary disorders is documented in Latin American traditional medicine. Leaves and seeds are described as expectorant and cardiotonic in multiple indigenous compendia. No human clinical evidence is available.

Bitter apricot kernel (xing ren) is used in TCM for bronchitis as an antitussive and expectorant. TCM clinical use lists bronchitis among its primary indications. The kernel promotes mucus clearance from the respiratory tract and has been incorporated in herbal preparations for bronchial conditions. Traditional use spans Chinese, Persian, and other Asian medical systems.

Traditional use of asparagus roots for bronchial conditions, including bronchial asthma and cough, is documented across multiple cultures. A. cochinchinensis dried roots have been listed in the Chinese Pharmacopoeia for asthma and cough since 1977. European traditional practice recorded use for 'bronchial asthma'. No clinical trial evidence exists.

Aster root has 2,000-plus years of documented use in TCM, Korean, and Japanese traditional medicine specifically for bronchitis management. Traditional use for chronic bronchitis is particularly well-documented across Asian medical traditions. Preclinical evidence from cell and animal models supports anti-inflammatory activity along the bronchitis-relevant TLR4/MyD88/NF-κB pathway, though no human bronchitis trials exist.

Balloon flower (Platycodon grandiflorus) root is a core Traditional Chinese and Korean medicine herb for bronchial congestion and bronchitis, used to expel phlegm and open the lungs. The 2025 Frontiers in Pharmacology systematic review on chronic bronchitis identifies its polysaccharides and platycodin D as suppressing mucin expression. Classified as an expectorant in both Chinese and Korean Pharmacopoeias.

Bamboo sap (Succus Bambusae/zhuli) and tabasheer (tianzhuhuang) are used in TCM for acute bronchitis, as documented in classical Chinese medical texts and modern TCM clinical practice. The ITM Online reference notes bamboo sap is used clinically for pneumonia and acute bronchitis. Indian traditional medicine similarly uses bamboo formulations for bronchial infections.

Basil is documented in traditional medicine across India, Brazil, and Africa for bronchitis and cough. The Frontiers in Pharmacology systematic review confirmed traditional use for bronchitis in multiple countries. Bronchodilatory properties of linalool metabolites provide pharmacological plausibility.

Bayberry leaf tea was historically used for bronchitis as part of North American folk medicine traditions. TCM also records bayberry use for respiratory inflammation. The herb's expectorant and astringent properties underpin this traditional use. No clinical evidence exists.

Belleric myrobalan is consistently cited for bronchitis across Ayurvedic, Unani, Siddha, and traditional Chinese medicine systems. The Chinese Pharmacopeia specifically lists T. bellirica for treating bronchitis. Its bronchodilatory, antispasmodic, and antimicrobial properties provide mechanistic support. Traditional use for bronchial conditions is among the most consistently documented applications of this herb.

Bronchitis is listed in multiple pharmacopoeia and aromatherapy references for black spruce. Its mucolytic (camphene), expectorant, and anti-inflammatory properties (bornyl acetate) are well established in traditional herbalism. The School of Aromatic Studies specifically lists it for bronchitis.

A. scholaris bark is traditionally indicated for bronchitis and chronic respiratory conditions in Ayurvedic, Unani, and Chinese medical systems. Its antitussive and expectorant activities have been confirmed in animal models, lending preclinical support, though no human clinical trials targeting bronchitis specifically have been published.

Boneset has a documented traditional role in acute bronchitis, attributed to its diaphoretic and mild expectorant actions. Lockwood's 1847 medical report (archived in PMC) listed bronchitis among its primary indications. Modern herbalists continue to use it for acute bronchitis with fever and mucus congestion. No clinical trials for bronchitis specifically have been performed.

Borage leaf has a well-documented traditional use for bronchitis, colds, and respiratory catarrh, recorded across European, Mediterranean, and other herbal traditions. It was used as an expectorant and anti-inflammatory. Traditional herbal monographs consistently cite this respiratory indication.

Cajuput oil is a well-documented traditional remedy for bronchitis across Southeast Asia and in European herbal practice, where it was historically valued as an inhalant. Its major constituent 1,8-cineole has clinical evidence (in pharmaceutical form) for improving bronchitis symptoms in RCTs, though these studies used isolated cineole, not cajuput oil itself. Cajuput is an ingredient in OTC bronchitis inhalant products.

Camphor has extensive traditional use for bronchitis across Asian and European medicine. Historical pharmacological texts report good outcomes for acute bronchitis. The Drugs in Context 2022 clinical review assessed a camphor-containing ointment for bronchial catarrh and hoarseness with high tolerability ratings. However, bronchitis-specific clinical trial evidence for camphor alone is lacking.

Caraway is traditionally used for bronchitis and respiratory infections in European and Ayurvedic herbal medicine. Its expectorant and antimicrobial properties are the basis for traditional use. A peer-reviewed scientific source confirms use in bronchopulmonary disorders as a cough remedy.

Cardamom has traditional use in Ayurvedic and South Asian medicine for bronchitis, bronchial congestion, and respiratory infections. Its expectorant, anti-inflammatory, and antimicrobial properties—primarily attributed to 1,8-cineole—provide pharmacological rationale. Clinical trial data specifically for bronchitis are absent.

A. aspera is widely documented for bronchitis use in Ayurveda, Siddha, Unani, and African folk systems. Its bronchodilator and anti-inflammatory properties provide pharmacological rationalization, but no specific bronchitis clinical study exists.

Germany's Commission E has formally approved chamomile for the treatment of coughs and bronchitis, representing one of the highest-quality regulatory endorsements of traditional use. Chamomile steam inhalation is a documented traditional application for bronchitis, colds, and mucous congestion. Human clinical trials specifically for bronchitis are absent.

Chen Pi is traditionally listed in Chinese Materia Medica for chronic bronchitis and is used in clinical TCM practice for cough with profuse phlegm. Its mucolytic volatile oils and anti-inflammatory flavonoids provide mechanistic rationale, though isolated clinical trials are unavailable.

Chickweed is consistently cited in herbal traditions and ethnobotanical records as a remedy for bronchitis, valued for its combined expectorant and soothing demulcent actions on the bronchial airways. Multiple herbal monographs document this use. No clinical evidence is available.

C. sinensis has a documented history of traditional use for bronchitis, cough, and respiratory congestion across European and Chinese herbal medicine. Grieve's classic herbal describes oils from oranges for chronic bronchitis. No dedicated human clinical RCTs on C. sinensis for bronchitis have been identified.

Clerodendrum indicum is explicitly listed in traditional systems of medicine for the treatment of bronchitis. The root and leaf juice mixed with ghee or ginger form the classical preparations used across India and Southeast Asia. This use is consistently documented across multiple ethnobotanical sources but lacks clinical validation.

Clove is traditionally used for bronchitis in Ayurvedic and folk medicine. Eugenol's anti-inflammatory, antimicrobial, and expectorant properties are relevant to bronchitis pathology.

Coltsfoot is among the most historically prominent herbs for bronchitis in both European and Chinese herbal medicine. In Europe, the leaves are used to treat bronchial infections; in China, the flower buds are preferred for acute and chronic bronchitis. No independent clinical trials exist.

Comfrey has a well-documented traditional use internally as an expectorant and soothing agent for bronchitis and dry cough, with its mucilaginous compounds coating irritated bronchial mucosa. Historical herbals and modern databases (RxList, drugs.com) list bronchitis among traditional indications. No clinical trials support this use, and oral comfrey is contraindicated due to pyrrolizidine alkaloid hepatotoxicity.

Commiphora myrrh has a well-documented traditional classification as an expectorant and antimicrobial agent for bronchitis across TCM, Ayurveda, Arabic, and European herbal medicine. ESCOP and historical pharmacopoeias recognize its respiratory applications. Clinical trial data is absent.

Damiana is listed in traditional medicine for coughs, bronchitis, and respiratory complaints. Maya Indians named it 'mis kok' meaning 'broom for asthma.' Traditional preparations include it as an expectorant and cough suppressant. No clinical studies on bronchitis exist.

Dog Rose has documented traditional use for respiratory conditions including bronchitis across multiple ethnopharmacological sources. Rosa canina is classified in the IJPS Journal systematic review as traditionally used for 'respiratory conditions such as bronchitis and colds.' No human clinical trials for bronchitis specifically have been conducted.

Elecampane (Inula helenium) has a centuries-long specific traditional use for bronchitis-associated cough in Western herbal and Eclectic medicine. It is listed as a proposed bronchitis treatment by the EBSCO evidence database. Its sesquiterpene lactone alantolactone is anti-inflammatory and the inulin content provides mucilaginous expectorant action.

Ephedra (Ephedra sinica, Ma Huang) has been used in Traditional Chinese Medicine for over 5,000 years for respiratory conditions including bronchitis and asthma. Its alkaloids ephedrine and pseudoephedrine are pharmacologically validated bronchodilators. German Commission E and WHO recognize Ephedra preparations for respiratory catarrh and cough.

Chronic bronchitis is a primary traditional indication for asafoetida documented across Ayurvedic, Unani, European, and Middle Eastern medicine. Expectorant activity via pulmonary elimination of volatile oil, smooth-muscle relaxation, and antimicrobial properties underpin this use.

C. forskohlii is historically documented in Ayurvedic medicine for bronchitis, sharing mechanistic overlap with its asthma indication via airway smooth-muscle relaxation. No clinical trials specifically for bronchitis have been identified.

Forsythia (Forsythia suspensa, Lian Qiao) is a key Traditional Chinese Medicine herb for acute respiratory infections including bronchitis and lung heat conditions. It is traditionally combined with honeysuckle in Yin Qiao San for respiratory infections. Its forsythosides and lignans have antiviral and anti-inflammatory activity. Evidence is primarily traditional and preclinical.

Ganoderma lucidum has a documented traditional Chinese medicine use for chronic bronchitis, with antitussive and bronchodilatory pharmacological properties identified in preclinical studies. Modern reviews affirm its potential for bronchitis management based on its anti-inflammatory and respiratory effects.

Ginger (Zingiber officinale) has traditional use in Ayurveda, TCM, and folk medicine specifically for bronchitis and cough. Anti-inflammatory effects in human bronchial epithelial cells (BEAS-2B) are published (Podlogar and Verspohl, 2012, Phytotherapy Research, PMID 21698672). Systematic reviews note limited high-quality RCT evidence for acute bronchitis specifically.

Goldenrod has traditional use for bronchitis as part of its documented role in upper respiratory catarrhal conditions. European and North American folk medicine list it for bronchial catarrh and associated cough. Its anticatarrhal and mild expectorant properties provide pharmacological plausibility. No clinical trials have evaluated goldenrod for bronchitis specifically.

Goldenseal is traditionally used for bronchitis as part of its broader mucous membrane and respiratory tract indications. Its antimicrobial and mucolytic-adjacent properties are the rationale. No clinical trials have confirmed efficacy for bronchitis.

Traditional Ayurvedic and Unani medicine use amla for bronchitis and other respiratory conditions. A clinical study in volunteers with smoking-related respiratory compromise documented cardio-respiratory improvements. Anti-inflammatory and antioxidant mechanisms support this use.

Bronchitis is among the most consistently cited traditional indications for GMT across Balkan ethnobotany, referenced in both peer-reviewed literature and the EMA assessment process. GMT's expectorant, anti-inflammatory, and antimicrobial properties are directly relevant. No human RCT in bronchitis has been published.

Green chiretta is documented in both TCM and Ayurveda as a treatment for bronchitis and acute respiratory bacterial/viral infections. It is traditionally used to clear lung heat, resolve phlegm, and reduce inflammatory exudation in the bronchial tree. Clinical ARTI data broadly support an anti-inflammatory and antiviral role relevant to bronchitis, though no dedicated bronchitis-specific clinical trials were identified.

Grindelia (Grindelia squarrosa, gumweed) is a traditional North American herb used specifically for bronchitis, asthma, and respiratory catarrh in Native American and Eclectic medicine traditions. It was included in the US Pharmacopeia and National Formulary for respiratory conditions. Its resinous grindelane diterpenes relax bronchial muscle and saponins provide expectorant activity.

In Ayurveda, guggul is described as aromatic and expectorant, useful for Kapha-type respiratory disorders including bronchitis, cough, and nasal catarrh. Inhalation of guggul fumes is a traditional application for respiratory conditions. No clinical trials exist for this indication.

Gumweed is another common name for Grindelia species, used traditionally for bronchitis and respiratory catarrh in North American herbal and Eclectic medicine. It was included in the US Pharmacopeia and National Formulary for respiratory indications and appears in authoritative herbal bronchitis treatment lists.

Bronchitis is among the traditional indications of H. spicatum documented in multiple systematic reviews, including Rawat et al. (2018). The plant is used in Ayurvedic formulations for bronchial conditions, and antihistaminic/bronchodilator preclinical data provide indirect mechanistic support.

The leaves and bark of H. antidysenterica are used in Ayurvedic, Unani, and British Materia Medica traditions for chronic bronchitis and chest infections. No modern clinical trials for bronchitis have been published; the evidence is ethnopharmacological.

Honey loquat syrup is a traditional Chinese medicine preparation combining honey and loquat leaf (Eriobotrya japonica) specifically used for bronchitis, cough, and respiratory inflammation. Loquat leaf is classified in TCM as an expectorant and anti-tussive herb. In vivo studies confirm antitussive and expectorant activities of loquat leaf decoction.

Honeysuckle (Lonicera japonica, Jin Yin Hua) is a foundational herb in Traditional Chinese Medicine for acute respiratory infections including bronchitis, cough, and lung heat conditions. It is listed among plants used for chronic bronchitis in authoritative herbal reviews. Its chlorogenic acid, luteolin, and quercetin content provide anti-inflammatory and antiviral properties.

White horehound (Marrubium vulgare) is listed in the EBSCO evidence database among proposed traditional bronchitis treatments. German Commission E approves horehound for non-productive cough and respiratory catarrh. Its diterpene marrubiin stimulates bronchial secretion, acting as a natural expectorant.

Hyssop (Hyssopus officinalis) has a centuries-long traditional use for bronchitis, cough, and respiratory inflammation listed in the EBSCO evidence database among proposed treatments for cough and bronchitis. German Commission E and EMA approve it for catarrh of the upper respiratory tract and non-productive cough. Its volatile oil constituent pinocamphone has expectorant and antispasmodic effects.

H. italicum EO has been traditionally used as an expectorant and for bronchitis. An in vitro study confirmed antibacterial and biofilm-inhibitory activity against respiratory tract pathogens including Haemophilus influenzae, Streptococcus pneumoniae, and Pseudomonas aeruginosa, providing partial scientific support for this traditional use.

Boswellia gum resin is documented in traditional Ayurvedic and Unani texts as a remedy for bronchitis and cough. It is listed alongside asthma among respiratory traditional indications. Anti-inflammatory 5-LOX inhibition is mechanistically relevant to airway inflammation in bronchitis.

Acacia nilotica leaves are traditionally employed to cure bronchitis across South Asian and African medicine. The plant's anti-inflammatory, antibacterial, and antispasmodic properties support this use. Traditional use for chest pain and respiratory complaints is documented.

Indigo leaves are documented in traditional Indian (Ayurvedic, Siddha, folk) and traditional Chinese medicine for the treatment of bronchitis. Leaves are specifically mentioned as used for 'cough, bronchitis, and fever' in multiple ethnobotanical records. No clinical human trial data exist.

I. racemosa is documented in Ayurvedic, Chinese Traditional Medicine, and Himalayan ethnomedicinal traditions for chronic bronchitis. The roots are classified as expectorant, bronchodilator, and anti-inflammatory in classical Ayurvedic texts. Scientific evidence is limited to animal and in vitro studies that support plausible mechanisms.

Jiaogulan is listed as a traditional treatment for chronic bronchitis in both the RxList and Drugs.com medical monographs, reflecting documented historical use in Chinese folk medicine for respiratory conditions including cough and chronic bronchitis.

Jujube is documented in traditional Korean, Chinese, and Ayurvedic medicine as effective for bronchitis, cough, and respiratory tract inflammation. Traditional pharmacopeia listings describe jujube syrup or decoction for throat irritation. No human clinical trials for bronchitis have been identified.

Kava has a documented traditional and historical use for bronchitis and respiratory tract conditions in Pacific Island and early Western herbal medicine, attributed to its anti-inflammatory, antimicrobial, and spasmolytic properties. No human clinical evidence supports this specific indication.

Knotweed (Polygonum aviculare species) has been used traditionally for bronchitis and cough. In TCM, Hu Zhang (P. cuspidatum) is used to resolve phlegm and ease cough. WebMD's monograph notes knotweed is used for bronchitis but states there is no good scientific evidence. The Chinese Pharmacopoeia records its use for bronchitis and cough.

Lemongrass is recorded in folk medicine as an antitussive (anti-cough) and respiratory remedy, with use for bronchitis documented in some traditional contexts. C. citratus is classified as antitussive in scientific reviews of its folk-medicine attributes. Antimicrobial and anti-inflammatory properties provide mechanistic support but clinical trials are absent.

Licorice root (Glycyrrhiza glabra) is documented by NCCIH and multiple traditional medicine authorities for cough and respiratory inflammation including bronchitis. German Commission E and ESCOP recognize licorice for catarrh of the upper respiratory tract. Its glycyrrhizin, flavonoids, and isoflavones provide anti-inflammatory, demulcent, and expectorant effects.

Bronchitis is a documented traditional indication of Syringa species in both Chinese/Asian traditional medicine and, for cough, in European ethnopharmacology. The BMC Chemistry and ScienceDirect genus reviews specifically list bronchitis among conditions treated with Syringa species. Asian species (S. reticulata) are documented for bronchial disease.

Lobelia (Lobelia inflata) is a traditional North American herb used extensively by Eclectic physicians specifically for bronchitis, asthma, and spasmodic cough. Lobeline, its primary alkaloid, acts as a respiratory stimulant and bronchial antispasmodic. It is listed among proposed traditional treatments for cough related to bronchitis in authoritative evidence databases.

Marjoram is documented in traditional European and Mediterranean herbal medicine for bronchitis, coughs, and chest congestion. Its expectorant classification and antimicrobial properties support this traditional application.

Marshmallow (Althaea officinalis) root has been used since ancient Greek and Egyptian times as a demulcent for bronchitis and cough. The EBSCO Research Starters evidence database lists it among proposed traditional bronchitis treatments. German Commission E recognizes marshmallow for dry irritative cough. Its high mucilage content coats and soothes inflamed bronchial mucous membranes.

Menthol has a long history of traditional use for bronchitis symptoms, particularly cough and chest tightness, via inhalation and topical chest application. Its TRPM8 activation suppresses cough reflex, but specific bronchitis clinical trials are not available.

Milkweed (chiefly A. tuberosa) has deep traditional use for bronchitis in both Indigenous North American and European-derived herbal medicine. It was listed in the US Pharmacopeia and National Formulary for respiratory conditions including bronchitis. UK herbalists also used the dried root for bronchitis. No clinical evidence supports efficacy.

Mullein (Verbascum thapsus) has been used for centuries across cultures for bronchitis, asthma, and respiratory ailments, specifically recognized by Eclectic physicians for irritable chronic bronchitis. The EBSCO evidence database lists it among proposed bronchitis treatments. Its mucilaginous leaves soothe inflamed bronchial membranes and saponins loosen mucus.

Mustard plasters applied to the chest have been used since at least the 19th century for bronchitis, and 'Mustard Poultices in the Treatment of Acute Bronchitis' was the subject of a published medical journal article as early as 1914. AITC vapors from the plaster are theorized to loosen mucus and improve airway circulation. No modern controlled clinical trials exist.

Myrrh is documented in Western and Ayurvedic herbal traditions as a treatment for bronchitis, used as an expectorant and chest rub. Chest rubs made from diluted myrrh essential oil are specifically described for bronchitis with thick phlegm. An expectorant action is classified in formal herbal monographs.

C. rotundus is listed in Ayurvedic pharmacopeias as a treatment for bronchitis. The antispasmodic and anti-inflammatory properties are mechanistically consistent with bronchial relief. Traditional use across Ayurvedic and Unani systems for respiratory conditions including bronchitis is documented.

Traditional use of onion for bronchitis and its associated cough is documented across multiple traditional medicine systems, explicitly cited in peer-reviewed pharmacological reviews. Onion's antibacterial, bronchodilatory, and anti-inflammatory properties provide mechanistic support for this traditional indication.

Ophiopogon japonicus has a well-documented history in TCM and encyclopedia sources for treating bronchitis and related chronic respiratory conditions. It is listed as an ingredient in multi-herb clinical formulas for chronic bronchitis with some clinical support at the formula level.

Chronic bronchitis is a documented traditional indication for ophiopogon root across multiple classical Chinese and Japanese medicine sources. The herb's lung-moistening and antitussive properties are applied to the dry cough and airway inflammation of bronchitis in yin deficiency patterns. No isolated human clinical trials for bronchitis specifically exist.

Bronchitis is a documented traditional indication for Citrus sinensis, with orange peel used historically in Chinese, Ayurvedic, and European herbal medicine for bronchial inflammation, phlegm clearance, and cough. Clinical evidence specific to orange for bronchitis is absent.

Bronchitis is one of the most historically consistent traditional indications for oregano, documented from ancient Greek medicine through medieval European and Turkish traditions. Oregano was used as an expectorant and antimicrobial agent for bronchial infections. Scientific evidence is preclinical only, with no human RCTs for bronchitis outcomes.

Chronic bronchitis is explicitly listed in the Chinese Pharmacopoeia (2010) as one of the primary indications for P. orientalis leaves. Classical TCM texts from 934 AD document this use. Anti-inflammatory and expectorant pharmacological activities provide mechanistic support.

Feverfew has documented traditional use for coughs, colds, and respiratory disorders including bronchitis across historical European herbalism. The PMC systematic review and NCCIH both list respiratory disorders as traditional indications. No clinical trials exist for this specific use.

Peach leaves (expectorant, demulcent) and seeds (antitussive) are documented in traditional medicine for bronchitis and chest congestion. The Eclectic tradition, TCM, and multiple botanical references cite this use. No clinical trials exist.

Peppermint (Mentha × piperita) essential oil is listed in the EBSCO evidence database as a proposed treatment for bronchitis and cough, particularly via inhalation/steam. German Commission E approves peppermint oil for catarrh of the upper respiratory tract. Menthol acts as a TRPM8 receptor agonist reducing cough reflex sensitivity and has mild decongestant and bronchospasmolytic properties.

Bromelain has been included in traditional formulas for bronchitis due to its mucolytic, anti-inflammatory, and immunomodulatory properties. Some clinical data support improvement of recovery from respiratory infections when bromelain is combined with antibiotics, but bronchitis-specific RCTs are lacking.

Pistacia integerrima galls are specifically documented in traditional Ayurvedic and Unani medicine for chronic bronchitis, described as expectorant and antitussive. Multiple published ethnopharmacological reviews and a 2014 PubMed paper confirm this traditional indication. Preclinical bronchodilatory and anti-inflammatory data provide supporting mechanistic evidence.

Platycodon grandiflorus (balloon flower root, Jie Geng) is a foundational herb in Traditional Chinese Medicine and Korean medicine for bronchial congestion, cough, and bronchitis, classified as an expectorant in the Chinese and Korean Pharmacopoeias. The 2025 Frontiers in Pharmacology systematic review on chronic bronchitis identifies its polysaccharides and platycodin D as suppressing mucin expression in CB models.

P. tenuifolia is traditionally used in TCM and Kampo as an expectorant and antitussive for bronchitis. A 2024 preclinical study confirmed that PT liquid extract reduced cough, phlegm, and bronchial inflammation in a mouse bronchitis model via PI3K/AKT and MAPK pathways, providing mechanistic validation of traditional use. No human RCTs have been conducted.

Polygala root has documented traditional use and animal-model-validated effects for bronchitis. A 2024 PubMed-indexed study using validated bronchitis mouse models confirmed antitussive, expectorant, and anti-inflammatory activity of the liquid extract.

P. marsupium heartwood has documented traditional use for bronchitis in Ayurveda. This is consistently cited in peer-reviewed ethnobotanical reviews and a PMC-indexed phytochemical study.

Oral Quillaja bark preparations have been used in traditional South American medicine specifically for bronchitis and cough for centuries. The saponins are thought to act as expectorants. No controlled human clinical trials support efficacy for bronchitis.

Radish is listed in traditional ethnobotanical and folk medicine sources, including RxList, as used for bronchitis and inflammation of the airways. TCM and Ayurveda use radish seed and root preparations to clear phlegm from the lungs and relieve cough. No clinical trials have evaluated this use.

Bronchitis is a well-documented traditional indication for red clover flowers across European and Asian herbal medicine. Multiple monograph sources cite its use as an expectorant and anti-inflammatory remedy for bronchitis. No clinical trial evidence has been identified.

Chronic bronchitis is among the most consistently mentioned traditional indications for Ceanothus americanus, appearing in Native American records, Eclectic materia medica, and contemporary herbalism. The expectorant and antispasmodic actions of the root are cited as the mechanism. No human clinical trials have assessed this use.

S. baicalensis is traditionally used in TCM for respiratory infections with cough and thick phlegm, conditions overlapping with bronchitis. Ben Cao Gang Mu documents use for upper respiratory infections and pneumonia. Baicalin's anti-inflammatory and antimicrobial properties are pharmacologically relevant to bronchitic inflammation.

Slippery elm (Ulmus rubra) bark is listed among proposed bronchitis treatments in the EBSCO Research Starters evidence database. It is listed in the United States Pharmacopeia as an emollient and demulcent. Its high mucilage content coats and soothes irritated bronchial mucous membranes and reduces cough reflex irritation.

Slippery elm bark is the primary medicinal part of Ulmus rubra, listed in the EBSCO Research Starters evidence database among proposed bronchitis treatments. It is listed in the US Pharmacopeia as an emollient and demulcent for irritated mucous membranes. Its mucilaginous properties soothe bronchial mucous membranes and reduce cough irritation.

Bronchitis is documented as a traditional indication for Solomon's seal as a demulcent and expectorant herb, particularly in Ayurvedic and Western herbal traditions. The herb soothes bronchial mucosa and facilitates mucus clearance from airways.

S. indicus is traditionally used for cough and chest conditions in Ayurveda and Siddha, encompassing bronchitis-type presentations. Preclinical bronchodilatory and antitussive activities provide mechanistic support.

Spruce essential oil is traditionally used in aromatherapy and folk herbal medicine for bronchitis, leveraging its mucolytic (camphene) and anti-inflammatory (bornyl acetate) terpene constituents. Inner bark infusions were used for bronchial inflammation by Indigenous peoples. European herbal traditions record spruce preparations for bronchial catarrh.

Stillingia root has a well-documented traditional use for bronchitis, recognized by Native American healers and later by 19th-century Eclectic physicians who employed it as an expectorant and respiratory stimulant. It was used to loosen congestion and ease chronic bronchial inflammation. No clinical trials have been conducted to confirm efficacy.

Traditional herbal medicine consistently records sunflower seeds, leaves, and flowers as treatments for bronchitis and respiratory infections. Leaf syrups and decoctions were used to clear bronchial phlegm. Historical monographs list bronchitis among the primary indications for sunflower seed preparations.

A. calamus is traditionally used in bronchitis across Ayurveda, Chinese medicine, and multiple folk traditions, attributed to its expectorant, antispasmodic, and anti-inflammatory properties. Bronchodilatory activity is confirmed preclinically. Traditional classification as an expectorant appears consistently across pharmacopeial references.

Tartarian aster root (Zi Wan) has been used in TCM for over 2,000 years specifically for bronchitis and cough with phlegm. Classical formulas such as Zhi Sou San, dating to around 1700 AD, incorporate it as a key ingredient for lung infections with coughing. Preclinical pharmacology confirms expectorant, antitussive, and antibacterial actions. No controlled human trials isolating its effect on bronchitis have been published.

Trichosanthes is used in TCM for bronchitis and related respiratory conditions involving productive cough and phlegm-heat. It is listed as an expectorant in both Chinese and Korean classical medicine and is attributed to the lung meridian. The fruit and peel are indicated specifically for respiratory phlegm-heat patterns overlapping with bronchitis symptoms. Evidence is traditional and pharmacopoeial.

Turmeric (Curcuma longa) has traditional use in Ayurveda and TCM for bronchitis and respiratory inflammation, supported by published anti-inflammatory evidence in bronchial tissue and inclusion in a 2026 Nutrients review of plants for RTIs. Medical News Today (2024, peer-reviewed) notes curcumin's anti-inflammatory properties but limited direct clinical trial evidence specifically for bronchitis.

Tylophora leaves have been used in Ayurvedic and folk medicine across India, Sri Lanka, and Bangladesh for bronchitis, alongside asthma and whooping cough. The plant is documented in the Indian Ayurvedic system of medicines as a remedy for bronchitis. While the anti-asthmatic clinical evidence indirectly supports bronchial use, no clinical trials have specifically targeted bronchitis as a standalone diagnosis.

Vasicinol is a quinazoline alkaloid component of Adhatoda vasica (Malabar nut), documented in the plant's alkaloid profile alongside vasicine and vasicinone. It is present in Vasaka preparations listed in the Indian Pharmacopoeia for bronchitis and respiratory use, contributing to the overall pharmacological activity of the traditional Ayurvedic and Unani bronchitis remedy.

Watercress has been used since the time of Hippocrates as a stimulant and expectorant in the treatment of coughs and bronchitis. Its traditional use for bronchitis is documented across European, Middle Eastern, and North African medical traditions. In Germany, watercress is approved for phytotherapy use. No clinical RCT specifically for bronchitis has been conducted.

White oak bark tea is traditionally used for bronchitis, where its tannins and expectorant constituents are thought to help clear mucus and reduce inflammation of the bronchial passages. This use is documented across multiple traditional herbal systems. No clinical trials have been conducted.

Bronchitis is listed among the traditional uses of wood betony in European and folk herbal medicine, alongside other respiratory tract conditions, justified by its expectorant and anti-inflammatory properties. No clinical evidence exists.

Chronic bronchitis is listed among the traditional TCM indications for X. strumarium in the J Ethnopharmacol 2016 study documenting its ethnopharmacological relevance. Xanthatin has shown anti-inflammatory effects in asthmatic mouse models. Traditional antitussive use is documented across multiple sources.